Another US approval delay for Takeda
This article was originally published in Scrip
Executive Summary
Takedahas suffered a US approval delay for another of its products, this time the proton pump inhibitor dexlansoprazole (TAK-390MR). The US FDAwould not be able to complete its review by the original Prescription Drug User Fee Act date in October, and this was now expected to take a further three months, the Japanese firm said. Its DPP-4 inhibitor alogliptin recently suffered a similar delay and now looks unlikely to be approved before the end of the year (Scrip Online, October 10th, 2008). Dexlansoprazole, a modified once-daily form of lansoprazole, was filed in December 2007 for treating the symptoms of gastro-oesophageal reflux disease and healing/maintenance use in erosive oesophagitis.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.